The Potential Role of Mesenchymal Stem Cell Therapy for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Human Clinical Trials.
Martin Cevallos-Cueva, Laura Ghanem, Taissa Novis et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy of mesenchymal stem cell (MSC) therapy for moderate-to-severe atopic dermatitis (AD) across five clinical trials, including four randomized controlled trials. The analysis of 236 participants revealed a pooled EASI-50 response rate of 46.76% at week 12, indicating potential benefits of MSC therapy in this patient population.
Key findings
- The pooled EASI-50 response rate at week 12 was 46.76% (95% CI: 32.36% to 61.72%).
- EASI-75 response rates were 17.41% (95% CI: 5.56% to 43.03%) at week 12.
- EASI-75 response rates increased to 23.97% (95% CI: 16.48% to 33.50%) at week 16.
- The pooled incidence of treatment-emergent adverse events was 26.86% (95% CI: 19.56% to 35.68%).
Why it matters
The findings suggest that MSC therapy may provide a new treatment avenue for patients with moderate-to-severe atopic dermatitis who do not respond adequately to existing therapies. Understanding its potential can help clinicians consider alternative options for managing this challenging condition.
What to keep in mind
The current evidence is based on small clinical trials, highlighting the need for larger studies to confirm findings.